aTyr Pharma reports Journal of Biological Chemistry paper showing anti-fibrotic effects of ATYR0101 in lung model

Bitget2026/10/13 12:09

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

aTyr Pharma published Journal of Biological Chemistry data showing anti-fibrotic activity for ATYR0101, a DARS-derived fusion protein.
Mechanism targets LTBP-1 to trigger myofibroblast apoptosis, with activity dependent on active TGF-β.
In a bleomycin lung fibrosis model, ATYR0101 reduced collagen content and Ashcroft score, outperforming nintedanib control.
Program remains in IND-enabling studies, with plans to enter the clinic in 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. aTyr Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610130800PRIMZONEFULLFEED9844343) on October 13, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

aTyr Pharma reports Journal of Biological Chemistry paper showing anti-fibrotic effects of ATYR0101 in lung model

You may also like

Crypto prices